Gemcitabine alone or plus cisplatin for biliary tract cancer?

被引：0
作者：
Werner Scheithauer
机构：
[1] Medical University of Vienna,Department of Internal Medicine and Cancer Center
来源：
Nature Reviews Clinical Oncology | 2010年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A randomized phase III trial that assessed treatment with cisplatin plus gemcitabine or gemcitabine alone for patients with advanced biliary tract cancer has provided evidence for a new standard treatment option for these patients. The therapeutic outcome (that is, overall survival, disease-free survival, and disease control rate), was significantly better in the combination arm with no increase in toxic effects.
引用
收藏
页码：554 / 555
页数：1
相关论文
共 50 条
[21]   Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers [J].
Ali Ogul ;
Mehmet Mutlu Kidi ;
Mahmut Buyuksimsek .
Journal of Gastrointestinal Cancer, 2021, 52 :294-299
[22]   Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers [J].
Ogul, Ali ;
Kidi, Mehmet Mutlu ;
Buyuksimsek, Mahmut .
JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (01) :294-299
[23]   EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE STUDY [J].
Hirano, G. ;
Takii, Y. ;
Kamihira, T. ;
Fujisawa, K. ;
Ichiki, Y. ;
Suzuki, T. ;
Matsuo, T. ;
Uraoka, S. ;
Aoki, K. -I. ;
Sakai, K. -I. ;
Ogawa, R. ;
Higuchi, M. .
ANNALS OF ONCOLOGY, 2012, 23 :121-121
[24]   Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis [J].
Maeda, Osamu ;
Shimokata, Tomoya ;
Mizutani, Takefumi ;
Inoue, Megumi ;
Matsuoka, Ayumu ;
Ota, Akiko ;
Mizuno, Takashi ;
Ebata, Tomoki ;
Nagino, Masato ;
Ando, Yuichi .
ANNALS OF ONCOLOGY, 2017, 28 :50-50
[25]   Combination of gemcitabine and cisplatin for biliary tract cancer: A platform to build on [J].
Razumilava, Nataliya ;
Gores, Gregory J. .
JOURNAL OF HEPATOLOGY, 2011, 54 (03) :577-578
[26]   Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer [J].
Ahn, Daniel H. ;
Reardon, Josh ;
Ahn, Chul W. ;
Bupathi, Manojkumar ;
Mikhail, Sameh ;
Wu, Christina Sing-Ying ;
Bekaii-Saab, Tanios .
INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (08) :1671-1675
[27]   Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab [J].
Rimini, Margherita ;
Loi, Eleonora ;
Rizzato, Mario Domenico ;
Pressiani, Tiziana ;
Vivaldi, Caterina ;
Gusmaroli, Eleonora ;
Antonuzzo, Lorenzo ;
Martinelli, Erika ;
Garajova, Ingrid ;
Giordano, Guido ;
Lucchetti, Jessica ;
Schirripa, Marta ;
Cornara, Noemi ;
Rossari, Federico ;
Vitiello, Francesco ;
Amadeo, Elisabeth ;
Persano, Mara ;
Piva, Vittoria Matilde ;
Balsano, Rita ;
Salani, Francesca ;
Pircher, Chiara ;
Cascinu, Stefano ;
Niger, Monica ;
Fornaro, Lorenzo ;
Rimassa, Lorenza ;
Lonardi, Sara ;
Scartozzi, Mario ;
Zavattari, Patrizia ;
Casadei-Gardini, Andrea .
TARGETED ONCOLOGY, 2024, 19 (02) :223-235
[28]   Clinical outcomes of gemcitabine, cisplatin plus S-1 in patients with advanced biliary tract cancer [J].
Niisato, Yusuke ;
Ishida, Hiroyasu ;
Onoda, Tsubasa ;
Shimoyamada, Yudai ;
Ito, Yuka ;
Yamaguchi, Takashi .
ANNALS OF ONCOLOGY, 2019, 30
[29]   Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC) [J].
Aqel, Osama ;
Shen, Yunrong ;
Alfayoumi, Ibrahim ;
Abraham, Ivo .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30]   A phase II trial of gemcitabine plus cisplatin (GP) in patients with inoperable biliary tract cancer (BTC). [J].
Park, JO ;
Kang, WK ;
Kim, TY ;
Lee, MA ;
Ahn, MJ ;
Kim, HK ;
Lee, NS ;
Lim, HY ;
Park, BJ ;
Kim, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :341S-341S
12345